On May 25, 2021 Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders inside and outside of the brain, reported that Dr. Milton Werner, Ph.D., Chief Executive Officer of Inhibikase, will present at the Jefferies Virtual Healthcare Conference (Press release, Inhibikase Therapeutics, MAY 25, 2021, View Source [SID1234580543]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Virtual Healthcare Conference
Date: Tuesday, June 1, 2021
Time: 3:30pm ET

The Company also announced a presentation by Dr. Werner at the LD Micro Virtual Invitational XI:

LD Micro Virtual Invitational XI
Date: Thursday, June 10, 2021
Time: 11:30am ET

Dr. Werner will present and discuss the clinical pharmacokinetics and adverse event profile of IkT-148009, the Company’s lead asset being developed for the treatment of Parkinson’s disease in the brain and gastrointestinal tract.

Webcasts of the presentations will be available for on-demand viewing under "News & Events" in the Investors section of the Company’s website, www.inhibikase.com. An archived replay of the webcasts will be available for approximately 30 days following each event.